Both recombinant and antibody-based TRAIL therapies have been developed to date for the treatment of many cancers, but resistance to death receptor-mediated apoptosis remains a significant barrier in the field of pancreatic cancer [34]. The gene discussed is TNFSF10; the disease is familial pancreatic carcinoma.